Deerfield Management Company, L.P. (Series C) Adc Therapeutics Sa Transaction History

Deerfield Management Company, L.P. (Series C)

  • $4.04 Billion
  • Q4 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
BUY
$4.66 - $10.31 $11.1 Million - $24.6 Million
2,390,297 New
2,390,297 $11.5 Million
Q4 2020

Feb 16, 2021
SELL
$25.26 - $38.02 $7.58 Million - $11.4 Million
-300,000 Closed
0 $0
Q3 2020

Nov 16, 2020
SELL
$32.87 - $51.05 $6.57 Million - $10.2 Million
-200,000 Reduced 40.0%
300,000 $9.9 Million
Q2 2020

Aug 14, 2020
BUY
$29.65 - $46.81 $14.8 Million - $23.4 Million
500,000 New
500,000 $23.4 Million

Others Institutions Holding ADCT

# of Institutions
85
Shares Held
55.3M
Call Options Held
24.1K
Put Options Held
44.7K
View Full List

About ADC Therapeutics SA

ADCT Quotes by TradingView
  • Ticker ADCT
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,645,296
  • Market Cap $130M
  • Description
  • ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma;...
More about ADCT
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email